Beijing-based medtech startup Shukun Technology confirmed with KrASIA on Monday that the company has scored RMB 200 million (USD 29.1 million) from investors, led by Qiming Venture Partners.
ThunderSoft (SHZ: 300496), Everest VC, and SPD Silicon Valley Bank all participated in this round, which comes shortly after the startup closed its RMB 200 million Series B+ round in June.
Shukun has been rolling out AI-powered software since 2017 when the company was founded. Their software aims to quickly read computed images from physical examinations, helping doctors diagnose lung disease, heart disease, strokes, and cancers.
New funds will be used for marketing its products to the medical sector, as well developing and commercializing new products as the company’s founder believes that AI and digital doctors will become more common in the long run with the digitalization of human lives in various aspects.
This article is part of KrASIA’s “China Brief” section, where KrASIA’s reporters will provide quick daily updates about the tech ecosystem in China.